A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

Last updated:
2026-07-25
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN FEMALE PARTICIPANTS WITH STRESS URINARY INCONTINENCE WHO HAVE OBESITY OR OVERWEIGHT (RESTRAIN-SUI)

Intervention/treatment:
ORFORGLIPRON (LY3502970)
Medical condition:
URINARY INCONTINENCE
Protocol code:
J2A-MC-GZPS
Control number:
300830
Status:
Recruiting
Approved:
September 12, 2025
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT07202884
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: FEMALE
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Role
CONTACT
Phone:
317-615-4559
Name
Physicians interested in becoming principal investigators please contact
Role
CONTACT
Sponsor
ELI LILLY CANADA INC

Locations

Alpha Recherche Clinique
Québec, G2J 0C4
RECRUITING
Name
Jonathan Cloutier
Role
PRINCIPAL_INVESTIGATOR
ALPHA Recherche Clinique
Québec, G3K 2P8
RECRUITING
Role
CONTACT
Phone:
418-847-1112
Name
Camille Walsh
Role
PRINCIPAL_INVESTIGATOR
Alpha Recherche Clinique - Lévis
Lévis, G6V 0C9
RECRUITING
Role
CONTACT
Phone:
418-380-1112
Name
Steeve Kwan Tat
Role
PRINCIPAL_INVESTIGATOR
CaRe Clinic
Red Deer, T4P 1K4
RECRUITING
Role
CONTACT
Phone:
1-587-797-4443
Name
Josias Badenhorst
Role
PRINCIPAL_INVESTIGATOR
Kelowna Health and Memory Centre
Kelowna, V1Y 5A8
RECRUITING
Name
Colleen Maytham
Role
PRINCIPAL_INVESTIGATOR
OCT Research ULC
Kelowna, V1Y 1Z9
RECRUITING
Role
CONTACT
Phone:
250-862-8141
Name
Mallory Myers
Role
PRINCIPAL_INVESTIGATOR
Sunnybrook Research Institute
Toronto, M4N 3M5
RECRUITING
Name
Sender Herschorn
Role
PRINCIPAL_INVESTIGATOR
The Fe/Male Health Centre
Oakville, L6H 3P1
RECRUITING
Role
CONTACT
Phone:
1 905 842 1393
Name
Richard Casey
Role
PRINCIPAL_INVESTIGATOR
Did you find what you were looking for?

Contacts and resources